About this paper
Should life science companies be expected to share patient-level data from their clinical trials? Groups such as the European Medicines Agency and the AllTrials campaign say yes; it's in the public interest to do so. Forward-thinking companies are taking bold steps toward data sharing because it's also good business and good science. This article summarizes discussion on the topic with industry leaders at the Clinical Trial Data Transparency Forum, sponsored by SAS, held in October 2013.
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions, SAS helps customers at more than 75,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world THE POWER TO KNOW®.